US · GNTA
Genenta Science S.p.A.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Milan, MI 20132
- Website
- genenta.com
Price · as of 2024-12-31
$0.73
Market cap 18.96M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $5.64 | ||||
| 2022 | $7.05 | ||||
| 2023 | $3.97 | ||||
| 2024 | $3.80 |
AI valuation
Our deep-learning model estimates Genenta Science S.p.A.'s (GNTA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.73
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GNTA | Genenta Science S.p.A. | $0.73 | 18.96M | — | — | — | — | -6.66 | 4.75 | — | -4.80 | — | 4.78 | 0.00% | — | — | -54.13% | -1295.77% | -47.95% | 0.00 | — | 6.89 | 6.72 | 0.47 | -2344.00% | — | -4434.00% | -10.53% | -2.97 | -828.69% | 0.00% | 0.00% | 1.48% | -4.78 | -7.48 | — | 8.82 |
| BRNS | Barinthus Biotherapeutics… | $0.58 | 23.85M | +43,665% | +73% | — | — | -0.63 | 0.30 | 2.59 | 1.08 | — | 0.36 | 100.00% | -454.07% | -408.00% | -38.62% | -152.56% | -32.65% | 0.09 | -1282.45 | 8.03 | 7.90 | 1.78 | -1885.00% | 176646.00% | -4705.00% | -76.97% | -1.85 | -67.01% | 0.00% | 0.00% | 0.00% | 0.88 | 2.01 | -4.00 | -1.79 |
| INMB | INmune Bio, Inc. | $1.29 | 34.29M | +2,143% | +149% | — | +12,808% | -3.80 | 4.98 | 11425.06 | -3.31 | -14.43 | 10.26 | 100.00% | -304535.71% | -300585.71% | -119.83% | -351.09% | -87.16% | 0.01 | — | 3.14 | 3.09 | 0.49 | 2635.00% | -9097.00% | 17847.00% | -20.86% | -4.62 | -274.72% | 0.00% | 0.00% | 0.00% | -3.27 | -4.18 | 9958.06 | 4.00 |
| IPSC | Century Therapeutics, Inc… | $2.32 | 202.78M | +1,581% | -88% | — | — | -0.41 | 0.32 | 7.82 | 0.75 | — | 0.41 | 100.00% | -2096.48% | -1920.87% | -73.14% | -320.94% | -35.46% | 0.33 | — | 1.50 | 1.47 | 0.04 | -3000.00% | 19481.00% | 804.00% | -214.09% | -0.85 | -256.24% | 0.00% | 0.00% | 10.59% | 0.61 | 0.76 | -12.74 | -3.99 |
| JUNS | Jupiter Neurosciences, In… | $0.53 | 18.25M | — | — | — | — | -7.90 | 4.62 | — | -7.18 | — | 4.62 | 0.00% | — | — | 299.46% | 208.79% | -76.83% | 0.05 | -12.45 | 2.31 | 1.88 | 1.62 | -3943.00% | — | 71318.00% | -20.28% | -1.95 | 264.16% | 0.00% | 0.00% | 29.93% | -5.09 | -4.02 | — | -1.31 |
| MDCX | Medicus Pharma Ltd. Commo… | $1.53 | 37.8M | — | — | — | — | -2.63 | 9.36 | — | -2.29 | — | 9.36 | 0.00% | — | — | -525.44% | 1700.21% | -295.90% | 0.10 | -35.21 | 2.33 | 1.81 | 0.34 | -2810.00% | — | 14643.00% | -34.93% | -4.44 | 1558.23% | 0.00% | 0.00% | 7.24% | -2.28 | -2.49 | — | -6.04 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| SKYE | Skye Bioscience, Inc. | $0.74 | 23.88M | — | — | — | — | -3.61 | 1.41 | — | -1.11 | — | 1.41 | 0.00% | — | — | -80.48% | -4256.79% | -62.73% | 0.01 | -31.20 | 16.32 | 15.77 | 2.69 | -8641.00% | — | 9221.00% | -27.97% | -5.82 | -3784.31% | 0.00% | 0.00% | 74.32% | -0.93 | -1.04 | — | 9.69 |
| TELO | Telomir Pharmaceuticals, … | $1.27 | 43.66M | — | — | — | — | -7.77 | 199.83 | — | 2652.56 | -28.50 | 199.83 | 0.00% | — | — | -810.18% | -813.89% | -542.25% | 0.15 | 2.82 | 1.94 | 1.86 | -24.43 | 2727.00% | — | 3137.00% | -3.95% | -7.45 | -337.09% | 0.00% | 0.00% | 0.99% | -10.40 | -25.11 | — | 50.93 |
About Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
- CEO
- Pierluigi Paracchi
- Employees
- 13
- Beta
- 0.57
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.73) − 1 = — (DCF, example).